{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Patients with Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"title":"Patients with Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"}]}],"title":"Patients with Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"title":"Patients with Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]}],"title":"Patients Not Evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Patients with Less Than Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Number of patients in each response category, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, summarized as follows for target lesion criteria (see RECIST v1.1 for additional details): complete response (CR),disappearance of target lesions; partial response (PR), \\>=30% decrease in sum of longest diameter of target lesions; progressive disease (PD), \\>=20% increase in sum of longest diameter (LD) of target lesions or appearance of new lesions; stable disease (SD), insufficient change in target lesions or new lesions to qualify as either PD or SD.\n\nPatients are categorized according to the best response achieved prior to occurrence of progressive disease, where best response hierarchy is CR\\>PR\\>SD\\>PD.","groups":[{"description":"Patients were to receive cetuximab 400 mg/m\\^2 IV over 60-120 minutes on days 1, 8, and 15 and oral placebo twice daily on days 1-21. After 19 patients were enrolled, the trial was amended to remove the placebo (and blinding) due to issues with placebo tablet solubility.","id":"OG000","title":"Arm A - Cetuximab"},{"description":"Patients received cetuximab 400 mg/m\\^2 IV over 60-120 minutes on days 1, 8, and 15 and oral sorafenib tosylate 400 mg by mouth twice daily on days 1-21.","id":"OG001","title":"Arm B - Cetuximab and Sorafenib Tosylate"}],"paramType":"NUMBER","populationDescription":"All patients with best overall response data. Patients are excluded if best overall response data is missing or if the patient is not evaluable for best overall response.","reportingStatus":"POSTED","timeFrame":"On-treatment date to date of disease progression (assessed up to 3 years)","title":"Best Response","type":"SECONDARY","unitOfMeasure":"participants"}